Back to Article
Antibiotic prescriptions for COVID-19 patients increased during the BA.5 period
World Journal of Medical Microbiology
| Vol 2, Issue 1
Table 1. Comparison with patients’ characteristicsbetween BA.1/2 period and BA.5 period in2022.
|
|
| Jan-Mar (n=135, BA.1) | Jul-Sep (n=160, BA.4/5) | p value | ||
| Age | 66.5+-16.0 |
| 68.7+-19.0 |
| 0.14 | |
| Antibiotics (+) | 14.8%(20/135) |
| 26.3% (42/160) |
| 0.016* | |
|
| Respiratory |
| 10.4%(14/135) | 16.9% (27/160) | 0.14 | |
|
| Urinary |
| 1.5%(2/135) |
| 0.6%(1/160) | 0.47 |
|
| Abdomen |
| 1.5%(2/135) |
| 5.0%(8/160) | 0.09 |
|
| Skin |
| 0.7%(1/135) |
| 1.9%(3/160) | 0.4 |
|
| Brain |
| 0 |
| 1.3%(2/160) | 0.19 |
|
| Bacteremia |
| 0.7%(1/135) |
| 0 | 0.28 |
|
| Unknown |
| 0 |
| 0.6%(1/160) | 0.36 |
| Total Mortality | 7.9%(10/135) |
| 1.7% (2/160) |
| 0.008** | |